{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:18:29Z","timestamp":1773080309318,"version":"3.50.1"},"reference-count":95,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:p>Objective. To conduct a meta-analysis of randomized, controlled trials of cephalosporin versus penicillin treatment of group A \u03b2-hemolytic streptococcal (GABHS) tonsillopharyngitis in children.<\/jats:p>\n               <jats:p>Methodology. Medline, Embase, reference lists, and abstract searches were conducted to identify randomized, controlled trials of cephalosporin versus penicillin treatment of GABHS tonsillopharyngitis in children. Trials were included if they met the following criteria: patients &amp;lt;18 years old, bacteriologic confirmation of GABHS tonsillopharyngitis, random assignment to antibiotic therapy of an orally administered cephalosporin or penicillin for 10 days of treatment, and assessment of bacteriologic outcome using a throat culture after therapy. Primary outcomes of interest were bacteriologic and clinical cure rates. Sensitivity analyses were performed to assess the impact of careful clinical illness descriptions, compliance monitoring, GABHS serotyping, exclusion of GABHS carriers, and timing of the test-of-cure visit.<\/jats:p>\n               <jats:p>Results. Thirty-five trials involving 7125 patients were included in the meta-analysis. The overall summary odds ratio (OR) for the bacteriologic cure rate significantly favored cephalosporins compared with penicillin (OR: 3.02; 95% confidence interval [CI]: 2.49\u20133.67, with the individual cephalosporins [cephalexin, cefadroxil, cefuroxime, cefpodoxime, cefprozil, cefixime, ceftibuten, and cefdinir] showing superior bacteriologic cure rates). The overall summary OR for clinical cure rate was 2.33 (95% CI: 1.84\u20132.97), significantly favoring the same individual cephalosporins. There was a trend for diminishing bacterial cure with penicillin over time, comparing the trials published in the 1970s, 1980s, and 1990s. Sensitivity analyses for bacterial cure significantly favored cephalosporin treatment over penicillin treatment when trials were grouped as double-blind (OR: 2.31; 95% CI: 1.39\u20133.85), high-quality (OR: 2.50; 95% CI: 1.85\u20133.36) trials with well-defined clinical status (OR: 2.12; 95% CI: 1.54\u20132.90), with detailed compliance monitoring (OR: 2.85; 95% CI: 2.33\u20133.47), with GABHS serotyping (OR: 3.10; 95% CI: 2.42\u20133.98), with carriers eliminated (OR: 2.51; 95% CI: 1.55\u20134.08), and with test of cure 3 to 14 days posttreatment (OR: 3.53; 95% CI: 2.75\u20134.54). Analysis of comparative bacteriologic cure rates for the 3 generations of cephalosporins did not show a difference.<\/jats:p>\n               <jats:p>Conclusions. This meta-analysis indicates that the likelihood of bacteriologic and clinical failure of GABHS tonsillopharyngitis is significantly less if an oral cephalosporin is prescribed, compared with oral penicillin.<\/jats:p>","DOI":"10.1542\/peds.113.4.866","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"866-882","source":"Crossref","is-referenced-by-count":125,"title":["Meta-analysis of Cephalosporin Versus Penicillin Treatment of Group A Streptococcal Tonsillopharyngitis in Children"],"prefix":"10.1542","volume":"113","author":[{"given":"Janet R.","family":"Casey","sequence":"first","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Pichichero","sequence":"additional","affiliation":[{"name":"Microbiology and Immunology, Elmwood Pediatric Group, University of Rochester, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"2021121006154993400_R1","doi-asserted-by":"crossref","unstructured":"Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics.1995;96:758\u2013764","DOI":"10.1542\/peds.96.4.758"},{"key":"2021121006154993400_R2","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Red Book; Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000"},{"key":"2021121006154993400_R3","unstructured":"World Health Organization. Rheumatic Fever and Rheumatic Heart Disease. Report of a WHO Study Group. Technical Report Series No. 764. Geneva, Switzerland: World Health Organization; 1988"},{"key":"2021121006154993400_R4","doi-asserted-by":"crossref","unstructured":"Stillerman M. Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis. Pediatr Infect Dis J.1986;5:649\u2013654","DOI":"10.1097\/00006454-198611000-00010"},{"key":"2021121006154993400_R5","doi-asserted-by":"crossref","unstructured":"Holm S, Henning C, Grahn E, Lomberg H, Staley H. Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Scand J Infect Dis.1995;27:221\u2013228","DOI":"10.3109\/00365549509019013"},{"key":"2021121006154993400_R6","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Casey JR, Mayes T, et al. Penicillin failure in streptococcal tonsillopharyngitis: causes and remedies. Pediatr Infect Dis J.2000;19:917\u2013923","DOI":"10.1097\/00006454-200009000-00035"},{"key":"2021121006154993400_R7","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics.2001;108:1180\u20131186","DOI":"10.1542\/peds.108.5.1180"},{"key":"2021121006154993400_R8","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J.1991;10:275\u2013281","DOI":"10.1097\/00006454-199104000-00002"},{"key":"2021121006154993400_R9","unstructured":"Deeter RG, Kalman DL, Rogan MP, Chow SC. Therapy for pharyngitis and tonsillitis caused by group A beta-hemolytic streptococci: a meta-analysis comparing the efficacy and safety of cefadroxil monohydrate versus oral penicillin V. Clin Ther.1992;14:740\u2013754"},{"key":"2021121006154993400_R10","doi-asserted-by":"crossref","unstructured":"Stillerman M. Comparison of cephaloglycin and penicillin in streptococcal pharyngitis. Clin Pharmacol Ther.1969;11:205\u2013213","DOI":"10.1002\/cpt1970112205"},{"key":"2021121006154993400_R11","unstructured":"Stillerman M, Isenberg HD. Streptococcal pharyngitis therapy: comparison of cyclacillin, cephalexin, and potassium penicillin V. Antimicrob Agents Chemother.1970;2:270\u2013276"},{"key":"2021121006154993400_R12","unstructured":"Disney FA, Breese BB, Green JL, Talpey WB, Tobin JR. Cephalexin and penicillin therapy of childhood beta-hemolytic streptococcal infections. Postgrad Med J.1971;47(suppl):47\u201351"},{"key":"2021121006154993400_R13","doi-asserted-by":"crossref","unstructured":"Stillerman M, Isenberg HD, Moody M. Streptococcal pharyngitis therapy. Am J Dis Child.1972;123:457\u2013461","DOI":"10.1001\/archpedi.1972.02110110085005"},{"key":"2021121006154993400_R14","unstructured":"Rabinovitch M, MacKenzie R, Brazeau M, Marks MI. Treatment of streptococcal pharyngitis. I. Clinical evaluation. Can Med Assoc J.1973;108:1271\u20131274"},{"key":"2021121006154993400_R15","unstructured":"Disney FA, Breese BB, Francis AB, Green JL, Talpey WB. The use of cefaclor in the treatment of beta-haemolytic streptococcal throat infections in children. Postgrad Med J.1979;55(suppl 4):50\u201352"},{"key":"2021121006154993400_R16","unstructured":"Ginsburg CM, McCracken GH Jr, Crow SD, Steinberg JB, Cope F. A controlled comparative study of penicillin V and cefadroxil therapy of group A streptococcal tonsillopharyngitis. J Int Med Res.1980;8:82\u201386"},{"key":"2021121006154993400_R17","doi-asserted-by":"crossref","unstructured":"Ginsburg CM, McCracken GH, Steinberg JB, et al. Treatment of group A streptococcal pharyngitis in children. Results of a prospective, randomized study of four antimicrobial agents. Clin Pediatr.1981;21:83\u201388","DOI":"10.1177\/000992288202100203"},{"key":"2021121006154993400_R18","doi-asserted-by":"crossref","unstructured":"Henness DM. A clinical experience with cefadroxil in upper respiratory tract infection. J Antimicrob Chemother.1982;10:125\u2013135","DOI":"10.1093\/jac\/10.suppl_B.125"},{"key":"2021121006154993400_R19","unstructured":"Randolph MA. Recurrence rate in streptococcal pharyngitis with b. i. d. cefadroxil or t. i. d. penicillin V-K. Today\u2019s Ther Trends.1984;2:1\u20136"},{"key":"2021121006154993400_R20","doi-asserted-by":"crossref","unstructured":"Gerber MA, Randolph MF, Chanatry J, Wright LL, Anderson LR, Kaplan EL. Once daily therapy for streptococcal pharyngitis with cefadroxil. J Pediatr.1986;109:531\u2013537","DOI":"10.1016\/S0022-3476(86)80139-1"},{"key":"2021121006154993400_R21","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Disney FA, Aronovitz GH, Ginsburg C, Stillerman M. A multicenter, randomized, single-blind evaluation of cefuroxime axetil and phenoxymethyl penicillin in the treatment of streptococcal pharyngitis. Clin Pediatr (Phila).1987;26:453\u2013458","DOI":"10.1177\/000992288702600904"},{"key":"2021121006154993400_R22","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Disney FA, Aronovitz GH, Talpey WB, Green JL, Francis AB. Randomized, single-blind evaluation of cefadroxil and phenoxymethyl penicillin in the treatment of streptococcal pharyngitis. Antimicrob Agents Chemother.1987;31:903\u2013906","DOI":"10.1128\/AAC.31.6.903"},{"key":"2021121006154993400_R23","unstructured":"Gooch WM 3rd, Swenson E, Higbee MD, Cocchetto DM, Evans EC. Cefuroxime axetil and penicillin V compared in the treatment of group A beta-hemolytic streptococcal pharyngitis. Clin Ther.1987;9:670\u2013677"},{"key":"2021121006154993400_R24","unstructured":"Goldfarb J, Lemon E, O\u2019Horo J, Blumer JL. Once-daily cefadroxil versus oral penicillin in the pediatric treatment of streptococcal pharyngitis. Clin Ther.1988;10:178\u2013182"},{"key":"2021121006154993400_R25","doi-asserted-by":"crossref","unstructured":"Milatovic D, Knauer J. Cefadroxil versus penicillin in the treatment of streptococcal tonsillopharyngitis. Eur J Clin Microbiol Infect Dis.1989;8:282\u2013288","DOI":"10.1007\/BF01963451"},{"key":"2021121006154993400_R26","unstructured":"Cerstelotte E, Vandenberghe P, Bradbury F, et al. Cefetamet pivoxil and penicillin V in the treatment of group A beta-haemolytic streptococcal pharyngitis. Acta Ther.1990;16:163\u2013173"},{"key":"2021121006154993400_R27","doi-asserted-by":"crossref","unstructured":"Holm SE, Roos K, Stromberg A. A randomized study of treatment of streptococcal pharyngotonsillitis with cefadroxil or phenoxymethyl penicillin (penicillin V). Pediatr Infect Dis J.1991;10:S68\u2013S71","DOI":"10.1097\/00006454-199110001-00015"},{"key":"2021121006154993400_R28","unstructured":"Reed BD, Huck W, Zazove P. Treatment of \u03b2-hemolytic streptococcal pharyngitis with cefaclor or penicillin. Efficacy and interaction with beta-lactamase-producing organisms in the pharynx. J Fam Pract.1991;32:138\u2013144"},{"key":"2021121006154993400_R29","doi-asserted-by":"crossref","unstructured":"Disney FA, Dillon H, Blumer JL, et al. Cephalexin and penicillin in the treatment of group A beta-hemolytic streptococcal throat infections. Am J Dis Child.1992;146:1324\u20131327","DOI":"10.1001\/archpedi.1992.02160230082024"},{"key":"2021121006154993400_R30","doi-asserted-by":"crossref","unstructured":"Ramet J, Pierard D, Vandenberghe P, De Boeck K. Comparative study of cefetamet pivoxil and penicillin V in the treatment of group A beta-hemolytic streptococcal pharyngitis. Chemotherapy.1992;38(suppl 2):33\u201337","DOI":"10.1159\/000239096"},{"key":"2021121006154993400_R31","doi-asserted-by":"crossref","unstructured":"Disney FA, Hanfling MJ, Hausinger SA. Loracarbef (LY163892) vs. penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis. Pediatr Infect Dis J.1992;11:S20\u2013S26","DOI":"10.1097\/00006454-199208001-00004"},{"key":"2021121006154993400_R32","doi-asserted-by":"crossref","unstructured":"Block SL, Hedrick JA, Tyler RD. Comparative study of the effectiveness of cefixime and penicillin V for the treatment of streptococcal pharyngitis in children and adolescents. Pediatr Infect Dis J.1992;11:919\u2013925","DOI":"10.1097\/00006454-199211110-00003"},{"key":"2021121006154993400_R33","doi-asserted-by":"crossref","unstructured":"Dajani AS, Kessler SL, Mendelson R, Uden DL, Todd WM. Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis\/tonsillitis. Pediatr Infect Dis J.1993;12:275\u2013279","DOI":"10.1097\/00006454-199304000-00003"},{"key":"2021121006154993400_R34","doi-asserted-by":"crossref","unstructured":"Gooch WM, McLinn SE, Aronovitz GH, et al. Efficacy of cefuroxime axetil suspension compared with that of penicillin V suspension in children with group A streptococcal pharyngitis. Antimicrob Agents Chemother.1993;37:159\u2013163","DOI":"10.1128\/AAC.37.2.159"},{"key":"2021121006154993400_R35","doi-asserted-by":"crossref","unstructured":"Milatovic D, Adam D, Hamilton H, Materman E. Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis. Antimicrob Agents Chemother.1993;37:1620\u20131623","DOI":"10.1128\/AAC.37.8.1620"},{"key":"2021121006154993400_R36","doi-asserted-by":"crossref","unstructured":"McCarty JM. Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis. Eur J Clin Microbiol Infect Dis.1994;13:846\u2013850","DOI":"10.1007\/BF02111351"},{"key":"2021121006154993400_R37","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Gooch MW, Rodriguez W, et al. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med.1994;148:1053\u20131060","DOI":"10.1001\/archpedi.1994.02170100051010"},{"key":"2021121006154993400_R38","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Mclinn SE, Gooch WM 3rd, Rodriguez W, Goldfarb J, Reidenberg BE. Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten Pharyngitis International Study Group. Pediatr Infect Dis J.1995;14:S102\u2013S107","DOI":"10.1097\/00006454-199507001-00006"},{"key":"2021121006154993400_R39","unstructured":"Gervaix A, Brighi L, Halperin DS, Suter S. Cefetamet pivoxil in the treatment of pharyngotonsillitis due to group A beta-hemolytic streptococci: preliminary report. J Chemother.1995;7(suppl 1):21\u201324"},{"key":"2021121006154993400_R40","doi-asserted-by":"crossref","unstructured":"Roos K, Larsson P. Loracarbef versus phenoxymethylpenicillin in the treatment of recurrent streptococcal pharyngotonsillitis. Scand J Infect Dis.1997;29:141\u2013145","DOI":"10.3109\/00365549709035874"},{"key":"2021121006154993400_R41","doi-asserted-by":"crossref","unstructured":"Nemeth MA, Gooch WM 3rd, Hedrick J, Slosberg E, Keyserling CH, Tack KJ. Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis. Clin Ther.1999;21:1525\u20131532","DOI":"10.1016\/S0149-2918(00)80007-7"},{"key":"2021121006154993400_R42","doi-asserted-by":"crossref","unstructured":"Gerber MA, Tanz RR, Kabat W, et al. Potential mechanisms for failure to eradicate group A streptococci from the pharynx. Pediatrics.1999;104:911\u2013917","DOI":"10.1542\/peds.104.4.911"},{"key":"2021121006154993400_R43","doi-asserted-by":"crossref","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clin Trials.1996;17:1\u201312","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2021121006154993400_R44","unstructured":"Peto R. Statistical aspects of cancer trials. In: Halnan KE, ed. Treatment of Cancer. London, England: Chapman and Hall; 1982:867\u2013871"},{"key":"2021121006154993400_R45","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.1986;7:177\u2013188","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2021121006154993400_R46","doi-asserted-by":"crossref","unstructured":"Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ.1994;309:1351\u20131355","DOI":"10.1136\/bmj.309.6965.1351"},{"key":"2021121006154993400_R47","doi-asserted-by":"crossref","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med.1988;318:1728\u20131733","DOI":"10.1056\/NEJM198806303182605"},{"key":"2021121006154993400_R48","unstructured":"Derrick CW, Dillon HC. Therapy for prevention of acute rheumatic fever. Circulation.1974;50:38"},{"key":"2021121006154993400_R49","unstructured":"Stillerman M. Cefatrizine and potassium phenoxymethyl penicillin in group A streptococcal pharyngitis. Abstract no. 185. Presented at the 16th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 1976"},{"key":"2021121006154993400_R50","unstructured":"Rodriguez WJ, Chhabra OP, Sait T, Akram S. Failure of penicillin (pen) to successfully treat group A streptococcus (GAS) pharyngotonsillitis (PT) as compared to a cephalosporin. Is it time to re-examine the golden standard [abstract]?Pediatr Res.1991;29:123A"},{"key":"2021121006154993400_R51","unstructured":"Green M, Schwartz B, Serdy C, Barbadore K, Facklam R, Wald E. A comparison of b. i. d. penicillin and daily cefadroxil to treat group A streptococcal (GAS) pharyngitis [abstract]. Pediatr Res.1998;43:143A"},{"key":"2021121006154993400_R52","unstructured":"Block SL, Hedrick JA, Chou C, Stickler T, Horn R. Cefditoren vs. penicillin for streptococcal pharyngitis in children. Abstract no. G-1538. Presented at the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001"},{"key":"2021121006154993400_R53","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Green JL, Francis AB, et al. Recurrent group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J.1998;17:809\u2013815","DOI":"10.1097\/00006454-199809000-00012"},{"key":"2021121006154993400_R54","doi-asserted-by":"crossref","unstructured":"Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it?Pediatr Infect Dis J.1993;12:268\u2013274","DOI":"10.1097\/00006454-199304000-00002"},{"key":"2021121006154993400_R55","unstructured":"Blumer JL, Goldfarb J. Meta-analysis in the evaluation of treatment for streptococcal pharyngitis: a review. Clin Ther.1994;16:604\u2013621"},{"key":"2021121006154993400_R56","unstructured":"Group A streptococcal infections: an era of growing concern. Proceedings of a symposium. May 31 and June 1, 1991. Pediatr Infect Dis J.1991;10:S3\u2013S73"},{"key":"2021121006154993400_R57","doi-asserted-by":"crossref","unstructured":"Pichichero ME. The rising incidence of penicillin treatment failures in group A streptococcal tonsillopharyngitis: an emerging role for the cephalosporins?Pediatr Infect Dis J.1991;10:S50\u2013S55","DOI":"10.1097\/00006454-199110001-00011"},{"key":"2021121006154993400_R58","doi-asserted-by":"crossref","unstructured":"DelMar C. Managing sore throat: a literature review. II. Do antibiotics confer benefit?Med J Aust.1992;156:644\u2013649","DOI":"10.5694\/j.1326-5377.1992.tb121463.x"},{"key":"2021121006154993400_R59","doi-asserted-by":"crossref","unstructured":"Bisno AL. Acute pharyngitis. N Engl J Med.2001;344:205\u2013211","DOI":"10.1056\/NEJM200101183440308"},{"key":"2021121006154993400_R60","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Disney FA, Talpey WB, et al. Adverse and beneficial effects of immediate treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin. Pediatr Infect Dis J.1987;6:635\u2013643","DOI":"10.1097\/00006454-198707000-00004"},{"key":"2021121006154993400_R61","doi-asserted-by":"crossref","unstructured":"Shulman ST, Gerber MA, Tanz RR, Markowitz M. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J.1994;13:1\u20137","DOI":"10.1097\/00006454-199401000-00002"},{"key":"2021121006154993400_R62","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol.2000;53:1119\u20131129","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"2021121006154993400_R63","doi-asserted-by":"crossref","unstructured":"Ginsburg CM, McCracken GH Jr, Crow SD, et al. Seroepidemiology of the group A streptococcal carriage state in a private pediatric practice. Am J Dis Child.1985;139:614\u2013617","DOI":"10.1001\/archpedi.1985.02140080084039"},{"key":"2021121006154993400_R64","doi-asserted-by":"crossref","unstructured":"Hoffman S. The throat carrier rate of group A and other beta-hemolytic streptococci among patients in general practice. Acta Pathol Microbiol Immunol Scand [B].1985;93:347\u2013351","DOI":"10.1111\/j.1699-0463.1985.tb02899.x"},{"key":"2021121006154993400_R65","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Marsocci SM, Murphy ML, Hoeger W, Green JL, Sorrento A. Incidence of streptococcal carriers in private pediatric practice. Arch Pediatr Adolesc Med.1999;153:624\u2013628","DOI":"10.1001\/archpedi.153.6.624"},{"key":"2021121006154993400_R66","doi-asserted-by":"crossref","unstructured":"Gastanaduy AS, Kaplan EL, Huwe BB, McKay C, Wannamaker LW. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet.1980;2(8193):498\u2013502","DOI":"10.1016\/S0140-6736(80)91832-2"},{"key":"2021121006154993400_R67","unstructured":"Kaplan EL, Gastanaduy AS, Huwe BB. The role of the carrier in treatment failures after antibiotic therapy for group A streptococci in the upper respiratory tract. J Lab Clin Med.1981;98:326\u2013335"},{"key":"2021121006154993400_R68","doi-asserted-by":"crossref","unstructured":"Tanz RR, Shulman ST, Barthel MJ, Willert C, Yogev R. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr.1985;106:876\u2013880","DOI":"10.1016\/S0022-3476(85)80229-8"},{"key":"2021121006154993400_R69","doi-asserted-by":"crossref","unstructured":"Gerber MA. Treatment failures and carriers: perception or problems?Pediatr Infect Dis J.1994;13:576\u2013579","DOI":"10.1097\/00006454-199406000-00036"},{"key":"2021121006154993400_R70","doi-asserted-by":"crossref","unstructured":"Davies HD, Low D, Schwartz B, et al. Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci. The Ontario GAS Study Group. Clin Infect Dis.1995;21:1294\u20131296","DOI":"10.1093\/clinids\/21.5.1294"},{"key":"2021121006154993400_R71","doi-asserted-by":"crossref","unstructured":"Standaert BB, Finney K, Taylor MT, et al. Comparison between cefprozil and penicillin to eradicate pharyngeal colonization of group A beta-hemolytic streptococci. Pediatr Infect Dis J.1998;17:39\u201343","DOI":"10.1097\/00006454-199801000-00009"},{"key":"2021121006154993400_R72","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Hoeger W, Marsocci SM, Murphy AM, Francis AB, Dragalin V. Variables influencing penicillin treatment outcome in streptococcal tonsillopharyngitis. Arch Pediatr Adolesc Med.1999;153:565\u2013570","DOI":"10.1001\/archpedi.153.6.565"},{"key":"2021121006154993400_R73","doi-asserted-by":"crossref","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet.1999;354:1896\u20131900","DOI":"10.1016\/S0140-6736(99)04149-5"},{"key":"2021121006154993400_R74","doi-asserted-by":"crossref","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ.1997;315:629\u2013634","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2021121006154993400_R75","doi-asserted-by":"crossref","unstructured":"Klassen TP, Wiebe N, Math M, et al. Abstracts of randomized controlled trials presented at the Society for Pediatric Research meeting: an example of publication bias. Arch Pediatr Adolesc Med.2002;156:474\u2013479","DOI":"10.1001\/archpedi.156.5.474"},{"key":"2021121006154993400_R76","doi-asserted-by":"crossref","unstructured":"Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA.1995;273:408\u2013412","DOI":"10.1001\/jama.273.5.408"},{"key":"2021121006154993400_R77","doi-asserted-by":"crossref","unstructured":"Frank PF, Miller LF. Antagonistic effect of a penicillinase-producing staphylococcus on penicillin therapy of a streptococcal throat infection. Am J Med Sci.1962;243:582\u2013585","DOI":"10.1097\/00000441-196205000-00005"},{"key":"2021121006154993400_R78","doi-asserted-by":"crossref","unstructured":"Brook I. The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis.1984;6:601\u2013607","DOI":"10.1093\/clinids\/6.5.601"},{"key":"2021121006154993400_R79","doi-asserted-by":"crossref","unstructured":"Brook I. Beta-lactamase-producing bacteria recovered after clinical failures with various penicillin therapy. Arch Otolaryngol.1984;110:228\u2013231","DOI":"10.1001\/archotol.1984.00800300020004"},{"key":"2021121006154993400_R80","doi-asserted-by":"crossref","unstructured":"Smith TD, Huskins WC, Kim KS, Kaplan EL. Efficacy of beta-lactamase-resistant penicillin and influence of penicillin tolerance in eradicating streptococci from the pharynx after failure of penicillin therapy for group A streptococcal pharyngitis. J Pediatr.1987;110:777\u2013782","DOI":"10.1016\/S0022-3476(87)80023-9"},{"key":"2021121006154993400_R81","doi-asserted-by":"crossref","unstructured":"Brook I. Emergence and persistence of beta-lactamase-producing bacteria in the oropharynx following penicillin treatment. Arch Otolaryngol Head Neck Surg.1988;114:667\u2013670","DOI":"10.1001\/archotol.1988.01860180081036"},{"key":"2021121006154993400_R82","doi-asserted-by":"crossref","unstructured":"Pichichero ME. Evidence for copathogenicity as a mechanism for bacterial resistance. Infect Dis Clin Pract.1998;(4 suppl):S248\u2013S253","DOI":"10.1097\/00019048-199811004-00007"},{"key":"2021121006154993400_R83","doi-asserted-by":"crossref","unstructured":"Sanders E. Bacterial interference. I. Its occurrence among the respiratory tract flora and characterization of inhibition of group A streptococci by Viridans streptococci. J Infect Dis.1969;120:698\u2013707","DOI":"10.1093\/infdis\/120.6.698"},{"key":"2021121006154993400_R84","doi-asserted-by":"crossref","unstructured":"Crowe CC, Sanders WE Jr, Longley S. Bacterial interference. II. Role of the normal throat flora in prevention of colonization by group A streptococcus. J Infect Dis.1973;128:527\u2013532","DOI":"10.1093\/infdis\/128.4.527"},{"key":"2021121006154993400_R85","doi-asserted-by":"crossref","unstructured":"Brook I, Gilmore JD. Evaluation of bacterial interference and beta-lactamase production in management of experimental infection with group A beta-hemolytic streptococci. Antimicrob Agents Chemother.1993;37:1452\u20131455","DOI":"10.1128\/AAC.37.7.1452"},{"key":"2021121006154993400_R86","doi-asserted-by":"crossref","unstructured":"Brook I, Gober AE. Role of bacterial interference and beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococcal pharyngotonsillitis. Arch Otolaryngol Head Neck Surg.1995;121:1405\u20131409","DOI":"10.1001\/archotol.1995.01890120061012"},{"key":"2021121006154993400_R87","doi-asserted-by":"crossref","unstructured":"Jones WF Jr, Finland M. Blood levels from orally administered penicillins G and V; relation to food intake. N Engl J Med.1955;18:754\u2013761","DOI":"10.1056\/NEJM195511032531802"},{"key":"2021121006154993400_R88","doi-asserted-by":"crossref","unstructured":"Holm SE, Ekedahl C. Comparative study of the penetration of penicillin V and cefadroxil into tonsils in man. J Antimicrob Chemother.1982;10(suppl B):121\u2013123","DOI":"10.1093\/jac\/10.suppl_B.121"},{"key":"2021121006154993400_R89","doi-asserted-by":"crossref","unstructured":"Peter G, Dudley MN. Clinical pharmacology of benzathine penicillin G. Pediatr Infect Dis J.1985;4:586\u2013591","DOI":"10.1097\/00006454-198509000-00059"},{"key":"2021121006154993400_R90","doi-asserted-by":"crossref","unstructured":"Kaplan EL. Benzathine penicillin G for treatment of group A streptococcal pharyngitis: a reappraisal in 1985. Pediatr Infect Dis J.1985;4:592\u2013596","DOI":"10.1097\/00006454-198509000-00060"},{"key":"2021121006154993400_R91","doi-asserted-by":"crossref","unstructured":"Stromberg A, Friberg U, Cars O. Concentrations of phenoxymethylpenicillin and cefadroxil in tonsillar tissue and tonsillar surface fluid. Eur J Clin Microbiol.1987;6:525\u2013529","DOI":"10.1007\/BF02014240"},{"key":"2021121006154993400_R92","doi-asserted-by":"crossref","unstructured":"Stjernquist-Desatnik A, Samuelsson P, Walder M. Penetration of penicillin V to tonsillar surface fluid in healthy individuals and in patients with acute tonsillitis. J Laryngol Otol.1993;107:309\u2013312","DOI":"10.1017\/S0022215100122893"},{"key":"2021121006154993400_R93","doi-asserted-by":"crossref","unstructured":"Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis.2002;35:113\u2013125","DOI":"10.1086\/340949"},{"key":"2021121006154993400_R94","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J.1997;16:680\u2013695","DOI":"10.1097\/00006454-199707000-00011"},{"key":"2021121006154993400_R95","doi-asserted-by":"crossref","unstructured":"Roos K, Claesson R, Persson U, Odegaard K. The economic cost of a streptococcal tonsillitis episode. Scand J Prim Health Care.1995;13:257\u2013260","DOI":"10.3109\/02813439508996772"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/4\/866\/1013317\/zpe00404000866.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/4\/866\/1013317\/zpe00404000866.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:11:50Z","timestamp":1639145510000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/113\/4\/866\/63978\/Meta-analysis-of-Cephalosporin-Versus-Penicillin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,4,1]]},"published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.113.4.866","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}